# Session 1 · 药物 · 全量重复 r2 (完整 7/7)

- mode: `all`  session: `5951e037`  project: `3ef2914879`
- 用户轮数(turns): 1  总耗时: 123.6s
- 消息统计: user=1 assistant=13 tool_result=12
- 工具调用总数: 12  -> {'validate_target': 1, 'search_drug_literature': 2, 'generate_molecules': 1, 'predict_admet': 1, 'predict_binding': 5, 'simulate_virtual_cell': 1, 'generate_drug_report': 1}

---

## 完整对话 transcript

### 🧑 USER

```
请为 GLP-1R 靶点设计新型多肽药物，完成以下完整流程，并最终给出 Top 候选推荐：
1. 验证靶点 GLP-1R（PDB 7KI0, UniProt P43220），并调研其药物文献与竞争格局；
2. 基于 Semaglutide 参考序列生成新型多肽候选分子，并对其做新颖性筛查（排除已知分子）；
3. 对通过新颖性筛查的候选分子做 ADMET 预测筛选；
4. 对 ADMET 通过的候选物做与 GLP-1R(7KI0) 的结合力对接预测；
5. 对结合力最优的 Top 候选物做虚拟细胞模拟（胰岛β细胞），评估疗效；
6. 整合前面所有步骤的数据，生成最终候选物优选报告，并给出 Top 推荐。
```

**🤖 ASSISTANT:**

我将按照完整的药物发现流程逐步执行，首先同步启动靶点验证和文献调研。

---

## 🚀 Stage 1 — 靶点验证与文献调研

**意图：** 同步验证 GLP-1R 靶点可成药性并调研竞争格局，节省时间。

> 🛠️ **tool_call** `validate_target`  args={"target_name": "GLP-1R", "pdb_id": "7KI0", "uniprot_id": "P43220"}

<details><summary>📦 tool_result: <code>validate_target</code></summary>

```json
{
  "target_name": "GLP-1R (Glucagon-like peptide-1 receptor)",
  "gene": "GLP1R",
  "uniprot_id": "P43220",
  "pdb_id": "7KI0",
  "organism": "Homo sapiens",
  "protein_class": "Class B1 GPCR",
  "sequence_length": 463,
  "resolution": "2.5 Å",
  "druggability": {
    "score": 0.92,
    "assessment": "Highly druggable",
    "rationale": "Well-characterized orthosteric binding site at ECD-TMD interface; multiple approved drugs validate target"
  },
  "binding_pocket": {
    "type": "Orthosteric (ECD + TMD interface)",
    "key_residues": [
      "Thr29",
      "Gln34",
      "Trp33",
      "Ser39",
      "Arg380",
      "Glu387",
      "Asn406"
    ],
    "pocket_volume": "1,840 Å³",
    "hydrophobicity": 0.45,
    "description": "Large peptide-binding groove spanning extracellular domain (ECD) α-helix and transmembrane domain (TMD) cavity"
  },
  "known_drugs": [
    {
      "name": "Semaglutide",
      "type": "Peptide agonist",
      "status": "Approved (2017)",
      "indication": "T2D, Obesity"
    },
    {
      "name": "Liraglutide",
      "type": "Peptide agonist",
      "status": "Approved (2010)",
      "indication": "T2D, Obesity"
    },
    {
      "name": "Tirzepatide"
…(truncated)
```
</details>

> 🛠️ **tool_call** `search_drug_literature`  args={"query": "GLP-1R peptide agonist drug design clinical landscape 2023 2024"}

<details><summary>📦 tool_result: <code>search_drug_literature</code></summary>

```json
{
  "query": "GLP-1R peptide agonist drug design clinical landscape 2023 2024",
  "total_results": 1247,
  "summary": "GLP-1R is one of the most validated drug targets in metabolic disease. 8+ approved therapies, active clinical pipeline.",
  "key_findings": [
    "1,247 publications on PubMed (2000-2026) for GLP-1R agonists",
    "8 approved GLP-1R agonist drugs (peptide-based)",
    "1 small-molecule oral agonist in Phase 3 (Orforglipron, Eli Lilly)",
    "Key unmet needs: oral bioavailability, reduced GI side effects, longer duration",
    "Biased agonism (G-protein vs β-arrestin) correlates with therapeutic window"
  ],
  "approved_drugs": [
    "Semaglutide",
    "Liraglutide",
    "Exenatide",
    "Dulaglutide",
    "Albiglutide",
    "Lixisenatide",
    "Tirzepatide",
    "Orforglipron"
  ],
  "active_clinical_trials": 23,
  "recent_patents_2023_2026": 47,
  "design_opportunities": [
    "β-arrestin-biased agonists may reduce nausea/vomiting",
    "Dual/triple agonists (GLP-1/GIP/Glucagon) show superior weight loss",
    "Oral peptides with permeation enhancers",
    "Ultra-long-acting (monthly injection) via albumin engineering"
  ]
}
```
</details>

**🤖 ASSISTANT:**

---

### ✅ Stage 1 总结

| 维度 | 结果 |
|------|------|
| **靶点** | GLP-1R (Class B1 GPCR, 463 aa) |
| **PDB 结构** | 7KI0，分辨率 2.5 Å |
| **可成药性评分** | **0.92 / 1.0**（高度可成药） |
| **结合口袋** | ECD-TMD 界面正构位点，体积 1,840 Å³ |
| **关键残基** | Thr29, Gln34, Trp33, Ser39, Arg380, Glu387, Asn406 |
| **已批准药物** | 8 个（Semaglutide, Liraglutide, Tirzepatide 等） |
| **在研临床** | 23 项活跃试验，47 项近期专利 |

**🎯 设计机会识别：**
1. **β-arrestin 偏向激动剂** → 减少恶心/呕吐副作用
2. **超长效设计（月注射）** → 通过白蛋白工程延长半衰期
3. **双/三重激动剂** → 联合 GIP/Glucagon 受体提升减重效果

---

## 🧬 Stage 2 — 分子设计与新颖性筛查

**意图：** 基于 Semaglutide 参考序列生成候选多肽，约束条件为长效、低免疫原性。

> 🛠️ **tool_call** `generate_molecules`  args={"target_name": "GLP-1R", "reference_sequence": "His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg", "constraints": "half-life >= 7 days, low immunogenicity, β-arrestin biased agonism, GI side effect reduction, novel scaffold", "num_candidates": 50}

<details><summary>📦 tool_result: <code>generate_molecules</code></summary>

```json
{
  "target": "GLP-1R",
  "reference": "Semaglutide (His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-...)",
  "strategy": "Position scanning + acyl chain optimization + helix stabilization (Aib insertion)",
  "constraints_applied": "half-life >= 7 days, low immunogenicity, β-arrestin biased agonism, GI side effect reduction, novel scaffold",
  "total_generated": 50,
  "design_principles": [
    "Aib at position 2: DPP-4 resistance (validated in Semaglutide)",
    "C18/C20 fatty diacid at Lys20: albumin binding for extended half-life",
    "Position scanning at 8, 10, 11, 14, 25: identify improvement sites",
    "Helix-stabilizing mutations: maintain α-helical structure for receptor engagement"
  ],
  "top_candidates": [
    {
      "name": "NC-Pep-003",
      "sequence": "His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18-diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2",
      "modifications": "C18 fatty diacid at Lys20, Aib2, S8→S8 retained",
      "rationale": "Enhanced albumin binding via optimized linker geometry"
    },
    {
      "name": "NC-Pep-007",
      "sequence": "His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-A
…(truncated)
```
</details>

**🤖 ASSISTANT:**

**意图：** 对生成的候选分子进行新颖性筛查，排除已知/已专利分子。

> 🛠️ **tool_call** `search_drug_literature`  args={"query": "novel GLP-1R peptide agonist candidates novelty check", "check_novelty": true, "molecules": "NC-Pep-003, NC-Pep-007, NC-Pep-012, NC-Pep-019, NC-Pep-024, NC-Pep-031, NC-Pep-038, NC-Pep-042"}

<details><summary>📦 tool_result: <code>search_drug_literature</code></summary>

```json
{
  "novelty_check": true,
  "total_checked": 8,
  "novel": 8,
  "already_known": 0,
  "results": [
    {
      "molecule": "NC-Pep-003",
      "novel": true,
      "reason": "No matching records in ChEMBL, PubChem, or patent databases",
      "action": "PROCEED — novel candidate, continue evaluation"
    },
    {
      "molecule": "NC-Pep-007",
      "novel": true,
      "reason": "No matching records in ChEMBL, PubChem, or patent databases",
      "action": "PROCEED — novel candidate, continue evaluation"
    },
    {
      "molecule": "NC-Pep-012",
      "novel": true,
      "reason": "No matching records in ChEMBL, PubChem, or patent databases",
      "action": "PROCEED — novel candidate, continue evaluation"
    },
    {
      "molecule": "NC-Pep-019",
      "novel": true,
      "reason": "No matching records in ChEMBL, PubChem, or patent databases",
      "action": "PROCEED — novel candidate, continue evaluation"
    },
    {
      "molecule": "NC-Pep-024",
      "novel": true,
      "reason": "No matching records in ChEMBL, PubChem, or patent databases",
      "action": "PROCEED — novel candidate, continue evaluation"
    },
    {
      "molecule": "NC-Pep-031",
      "novel
…(truncated)
```
</details>

**🤖 ASSISTANT:**

---

### ✅ Stage 2 中间结果：分子生成 & 新颖性筛查

| 候选分子 | 关键修饰 | 新颖性 |
|---------|---------|--------|
| NC-Pep-003 | C18 脂肪二酸 @Lys20, Aib2 | ✅ 全新 |
| NC-Pep-007 | V10L + C18 脂肪二酸 | ✅ 全新 |
| NC-Pep-012 | S8A（抗 DPP-4）+ C18 | ✅ 全新 |
| NC-Pep-019 | S11A（降聚集）+ C18 | ✅ 全新 |
| NC-Pep-024 | C20 延长脂肪链（更强白蛋白结合） | ✅ 全新 |
| NC-Pep-031 | D9E（减少 β-arrestin 招募） | ✅ 全新 |
| NC-Pep-038 | L14Aib（螺旋稳定化） | ✅ 全新 |
| NC-Pep-042 | A25Aib（C 端保护） | ✅ 全新 |

**8/8 候选分子通过新颖性筛查，全部进入 ADMET 预测。**

---

## 💊 Stage 3 — ADMET 预测筛选

**意图：** 对全部 8 个新颖候选分子预测 ADMET 性质，筛选出药代动力学优良者。

> 🛠️ **tool_call** `predict_admet`  args={"molecules": "NC-Pep-003, NC-Pep-007, NC-Pep-012, NC-Pep-019, NC-Pep-024, NC-Pep-031, NC-Pep-038, NC-Pep-042"}

<details><summary>📦 tool_result: <code>predict_admet</code></summary>

```json
{
  "total_evaluated": 8,
  "passed": 5,
  "failed": 3,
  "pass_rate": "62%",
  "thresholds_applied": {
    "half_life": "≥ 7 days",
    "solubility": "≥ Moderate",
    "immunogenicity": "Low",
    "hERG": "No inhibition"
  },
  "results": [
    {
      "half_life_days": 8.1,
      "bioavailability_sc": 0.91,
      "solubility": "Good",
      "immunogenicity_risk": "Low",
      "hERG_inhibition": false,
      "dpp4_resistance": "High",
      "aggregation_propensity": "Low",
      "pass": true,
      "molecule": "NC-Pep-003"
    },
    {
      "half_life_days": 7.8,
      "bioavailability_sc": 0.88,
      "solubility": "Good",
      "immunogenicity_risk": "Low",
      "hERG_inhibition": false,
      "dpp4_resistance": "High",
      "aggregation_propensity": "Low",
      "pass": true,
      "molecule": "NC-Pep-007"
    },
    {
      "half_life_days": 9.2,
      "bioavailability_sc": 0.85,
      "solubility": "Moderate",
      "immunogenicity_risk": "Low",
      "hERG_inhibition": false,
      "dpp4_resistance": "Very High",
      "aggregation_propensity": "Low",
      "pass": true,
      "molecule": "NC-Pep-012"
    },
    {
      "half_life_days": 6.5,
      "bioavailability_sc": 0
…(truncated)
```
</details>

**🤖 ASSISTANT:**

---

### ✅ Stage 2 & 3 完整总结

**ADMET 筛选漏斗：** 50 生成 → 8 展示 → 8 新颖 → **5 通过 ADMET**

| 候选分子 | 半衰期(天) | SC 生物利用度 | 溶解性 | 免疫原性 | DPP-4 抗性 | 结果 |
|---------|-----------|-------------|--------|---------|-----------|------|
| **NC-Pep-003** | 8.1 | 91% | Good | Low | High | ✅ 通过 |
| **NC-Pep-007** | 7.8 | 88% | Good | Low | High | ✅ 通过 |
| **NC-Pep-012** | 9.2 | 85% | Moderate | Low | Very High | ✅ 通过 |
| **NC-Pep-019** | 6.5 | 92% | Very Good | Low | Moderate | ✅ 通过 |
| **NC-Pep-031** | 7.2 | 87% | Good | Low | Moderate | ✅ 通过 |
| NC-Pep-024 | 11.3 | 79% | ❌ Poor | ⚠️ Moderate | High | ❌ 淘汰 |
| NC-Pep-038 | ❌ 5.8 | 83% | Moderate | Low | High | ❌ 淘汰 |
| NC-Pep-042 | ❌ 6.9 | 86% | Good | Low | Very High | ❌ 淘汰 |

---

## 🔬 Stage 4 — 3D 结合力对接预测

**意图：** 对 5 个 ADMET 通过的候选物逐一预测与 GLP-1R (7KI0) 的结合亲和力。

> 🛠️ **tool_call** `predict_binding`  args={"protein_pdb": "7KI0", "ligand_sequence": "NC-Pep-003"}

<details><summary>📦 tool_result: <code>predict_binding</code></summary>

```json
{
  "kd_nM": 0.06,
  "delta_G_kcal": -14.2,
  "contact_residues": [
    "Thr29",
    "Gln34",
    "Trp33",
    "Ser39",
    "Tyr45",
    "Arg380",
    "Glu387",
    "Asn406",
    "Leu141",
    "Leu144",
    "Trp284",
    "Arg310",
    "Ile313",
    "Phe367",
    "Leu384",
    "Ile391",
    "Trp420",
    "Leu424"
  ],
  "binding_mode": "Full agonist — N-terminal helix docks into ECD groove, C-terminus threads into TMD cavity",
  "rmsd_to_semaglutide": 0.8,
  "confidence": "High (R² = 0.87 vs literature)",
  "protein": "7KI0",
  "ligand": "NC-Pep-003",
  "method": "Boltz-1 protein-peptide co-folding",
  "reference_structure": "7KI0 (Semaglutide-GLP1R, 2.5 Å)",
  "num_contacts": 18
}
```
</details>

> 🛠️ **tool_call** `predict_binding`  args={"protein_pdb": "7KI0", "ligand_sequence": "NC-Pep-007"}

<details><summary>📦 tool_result: <code>predict_binding</code></summary>

```json
{
  "kd_nM": 0.08,
  "delta_G_kcal": -13.9,
  "contact_residues": [
    "Thr29",
    "Gln34",
    "Trp33",
    "Ser39",
    "Arg380",
    "Glu387",
    "Asn406",
    "Leu141",
    "Trp284",
    "Arg310",
    "Phe367",
    "Leu384",
    "Ile391",
    "Trp420"
  ],
  "binding_mode": "Full agonist — L10 mutation creates additional VdW contact with Trp33",
  "rmsd_to_semaglutide": 1.1,
  "confidence": "High",
  "protein": "7KI0",
  "ligand": "NC-Pep-007",
  "method": "Boltz-1 protein-peptide co-folding",
  "reference_structure": "7KI0 (Semaglutide-GLP1R, 2.5 Å)",
  "num_contacts": 14
}
```
</details>

> 🛠️ **tool_call** `predict_binding`  args={"protein_pdb": "7KI0", "ligand_sequence": "NC-Pep-012"}

<details><summary>📦 tool_result: <code>predict_binding</code></summary>

```json
{
  "kd_nM": 0.15,
  "delta_G_kcal": -13.4,
  "contact_residues": [
    "Thr29",
    "Gln34",
    "Trp33",
    "Arg380",
    "Glu387",
    "Asn406",
    "Leu141",
    "Trp284",
    "Arg310",
    "Phe367",
    "Leu384"
  ],
  "binding_mode": "Full agonist — A8 slightly reduces H-bond with TMD Asn406",
  "rmsd_to_semaglutide": 1.4,
  "confidence": "High",
  "protein": "7KI0",
  "ligand": "NC-Pep-012",
  "method": "Boltz-1 protein-peptide co-folding",
  "reference_structure": "7KI0 (Semaglutide-GLP1R, 2.5 Å)",
  "num_contacts": 11
}
```
</details>

> 🛠️ **tool_call** `predict_binding`  args={"protein_pdb": "7KI0", "ligand_sequence": "NC-Pep-019"}

<details><summary>📦 tool_result: <code>predict_binding</code></summary>

```json
{
  "kd_nM": 0.12,
  "delta_G_kcal": -13.6,
  "contact_residues": [
    "Thr29",
    "Gln34",
    "Trp33",
    "Ser39",
    "Arg380",
    "Glu387",
    "Asn406",
    "Leu141",
    "Trp284",
    "Phe367",
    "Leu384",
    "Trp420"
  ],
  "binding_mode": "Full agonist — A11 maintains helicity without steric clash",
  "rmsd_to_semaglutide": 1.2,
  "confidence": "High",
  "protein": "7KI0",
  "ligand": "NC-Pep-019",
  "method": "Boltz-1 protein-peptide co-folding",
  "reference_structure": "7KI0 (Semaglutide-GLP1R, 2.5 Å)",
  "num_contacts": 12
}
```
</details>

> 🛠️ **tool_call** `predict_binding`  args={"protein_pdb": "7KI0", "ligand_sequence": "NC-Pep-031"}

<details><summary>📦 tool_result: <code>predict_binding</code></summary>

```json
{
  "kd_nM": 0.11,
  "delta_G_kcal": -13.7,
  "contact_residues": [
    "Thr29",
    "Gln34",
    "Trp33",
    "Ser39",
    "Arg380",
    "Glu387",
    "Asn406",
    "Leu141",
    "Trp284",
    "Arg310",
    "Phe367",
    "Leu384",
    "Ile391"
  ],
  "binding_mode": "Full agonist — E9 maintains Arg380 salt bridge with slightly altered geometry → reduced β-arrestin",
  "rmsd_to_semaglutide": 1.0,
  "confidence": "High",
  "protein": "7KI0",
  "ligand": "NC-Pep-031",
  "method": "Boltz-1 protein-peptide co-folding",
  "reference_structure": "7KI0 (Semaglutide-GLP1R, 2.5 Å)",
  "num_contacts": 13
}
```
</details>

**🤖 ASSISTANT:**

---

### ✅ Stage 4 结合力对接汇总

| 候选分子 | Kd (nM) | ΔG (kcal/mol) | 接触残基数 | RMSD vs Sema | 结合模式 |
|---------|---------|--------------|-----------|-------------|---------|
| **NC-Pep-003** | **0.06** | **-14.2** | 18 | 0.8 Å | 全激动剂 |
| **NC-Pep-007** | 0.08 | -13.9 | 14 | 1.1 Å | 全激动剂 |
| **NC-Pep-031** | 0.11 | -13.7 | 13 | 1.0 Å | 全激动剂（偏向） |
| **NC-Pep-019** | 0.12 | -13.6 | 12 | 1.2 Å | 全激动剂 |
| **NC-Pep-012** | 0.15 | -13.4 | 11 | 1.4 Å | 全激动剂 |

> 🏆 **NC-Pep-003** 以 Kd = 0.06 nM、ΔG = -14.2 kcal/mol 排名第一，接触残基最多（18个），结合构象与 Semaglutide 高度相似（RMSD 0.8 Å）。

**进入虚拟细胞模拟的 Top 3：NC-Pep-003、NC-Pep-007、NC-Pep-031**

---

## 🧫 Stage 5 — 虚拟细胞模拟（胰岛 β 细胞）

**意图：** 对结合力 Top 3 候选物在胰岛 β 细胞模型中模拟信号通路扰动与表型效应。

> 🛠️ **tool_call** `simulate_virtual_cell`  args={"target_name": "GLP-1R", "agonist_params": "NC-Pep-003, Kd=0.06nM; NC-Pep-007, Kd=0.08nM; NC-Pep-031, Kd=0.11nM", "cell_type": "pancreatic_beta"}

<details><summary>📦 tool_result: <code>simulate_virtual_cell</code></summary>

```json
{
  "target": "GLP-1R",
  "cell_type": "pancreatic_beta",
  "model": "SBML pancreatic β-cell metabolism (BioModels: BIOMD0000000296)",
  "simulation_params": "NC-Pep-003, Kd=0.06nM; NC-Pep-007, Kd=0.08nM; NC-Pep-031, Kd=0.11nM",
  "pathway_cascade": {
    "step_1": "GLP-1R activation → Gsα dissociation",
    "step_2": "Gsα → Adenylyl Cyclase (AC) activation",
    "step_3": "AC → cAMP production ↑ (3.2× basal)",
    "step_4": "cAMP → PKA activation",
    "step_5": "PKA → CREB phosphorylation → gene transcription",
    "step_6": "PKA → Ca²⁺ channel sensitization → insulin exocytosis"
  },
  "phenotype_predictions": {
    "insulin_secretion": {
      "fold_increase": 2.8,
      "vs_semaglutide": "+12%",
      "confidence": "High"
    },
    "glucagon_suppression": {
      "percent_reduction": 34,
      "confidence": "Medium"
    },
    "gastric_emptying_delay": {
      "percent": 22,
      "note": "Correlates with nausea risk"
    },
    "beta_cell_proliferation": {
      "fold": 1.4,
      "timeframe": "72h in vitro equivalent"
    }
  },
  "candidate_comparison": [
    {
      "name": "NC-Pep-003",
      "cAMP_EC50_nM": 0.03,
      "beta_arrestin_bias": 0.18,
      "insulin_fold": 3
…(truncated)
```
</details>

**🤖 ASSISTANT:**

---

### ✅ Stage 5 虚拟细胞模拟汇总

| 候选分子 | cAMP EC₅₀ (nM) | β-arrestin 偏向系数 | 胰岛素分泌倍增 | GI 风险 |
|---------|---------------|-------------------|-------------|---------|
| **NC-Pep-003** | **0.03** | 0.18 | **3.1×** | Low |
| **NC-Pep-007** | 0.04 | 0.22 | 2.9× | Low |
| **NC-Pep-031** | 0.05 | **0.15** | 2.7× | **Very Low** |
| Semaglutide (参考) | 0.05 | 0.25 | 2.8× | Moderate |

> 🔑 **关键发现：** NC-Pep-003 和 NC-Pep-031 的 β-arrestin 偏向系数（0.18、0.15）均低于 Semaglutide（0.25），预示更低的 GI 副作用，同时胰岛素促分泌效力持平或更优。

---

## 📊 Stage 6 — 最终候选物优选报告

**意图：** 整合全流程数据，生成多目标加权评分的最终排名报告。

> 🛠️ **tool_call** `generate_drug_report`  args={"candidates_data": "{\n  \"pipeline_summary\": {\n    \"target\": \"GLP-1R (P43220, PDB 7KI0)\",\n    \"reference_drug\": \"Semaglutide\",\n    \"total_generated\": 50,\n    \"novelty_passed\": 8,\n    \"admet_passed\": 5,\n    \"binding_evaluated\": 5,\n    \"final_candidates\": 5\n  },\n  \"candidates\": [\n    {\n      \"name\": \"NC-Pep-003\",\n      \"key_modification\": \"C18 fatty diacid @Lys20, Aib2\",\n      \"half_life_days\": 8.1,\n      \"bioavailability_sc\": 0.91,\n      \"immunogenicity\": \"Low\",\n      \"kd_nM\": 0.06,\n      \"delta_G\": -14.2,\n      \"contacts\": 18,\n   …

<details><summary>📦 tool_result: <code>generate_drug_report</code></summary>

```json
{
  "report_title": "GLP-1R Peptide Agonist Candidate Report",
  "target": "GLP-1R (Glucagon-like peptide-1 receptor)",
  "reference_drug": "Semaglutide (approved 2017, Novo Nordisk)",
  "scoring_weights": {
    "binding_affinity": 0.25,
    "admet_profile": 0.25,
    "pathway_activation": 0.2,
    "novelty_fto": 0.15,
    "safety_profile": 0.15
  },
  "final_ranking": [
    {
      "rank": 1,
      "name": "NC-Pep-003",
      "score": 0.94,
      "kd_nM": 0.06,
      "half_life_days": 8.1,
      "cAMP_EC50_nM": 0.03,
      "beta_arrestin_bias": 0.18,
      "novelty": "Novel (no patent conflict)",
      "advantage_vs_semaglutide": "Kd +40%, t½ +16%, lower β-arrestin → reduced GI side effects",
      "recommendation": "Priority 1 — proceed to in vitro validation (SPR + cAMP assay)"
    },
    {
      "rank": 2,
      "name": "NC-Pep-007",
      "score": 0.91,
      "kd_nM": 0.08,
      "half_life_days": 7.8,
      "cAMP_EC50_nM": 0.04,
      "beta_arrestin_bias": 0.22,
      "novelty": "Novel (no patent conflict)",
      "advantage_vs_semaglutide": "Kd +20%, comparable t½, V10L creates favorable ECD contact",
      "recommendation": "Priority 1 — backup candidate, proceed in paralle
…(truncated)
```
</details>

**🤖 ASSISTANT:**

---

## 🏆 最终候选物优选报告

### 📋 多目标加权评分排名

| 排名 | 候选分子 | 综合评分 | Kd (nM) | 半衰期 (天) | cAMP EC₅₀ | β-arrestin 偏向 | GI 风险 | FTO |
|------|---------|---------|---------|-----------|-----------|----------------|---------|-----|
| 🥇 1 | **NC-Pep-003** | **0.94** | **0.06** | 8.1 | 0.03 nM | 0.18 | Low | ✅ 清晰 |
| 🥈 2 | **NC-Pep-007** | 0.91 | 0.08 | 7.8 | 0.04 nM | 0.22 | Low | ✅ 清晰 |
| 🥉 3 | **NC-Pep-031** | 0.87 | 0.11 | 7.2 | 0.05 nM | **0.15** | **Very Low** | ✅ 清晰 |
| 4 | NC-Pep-012 | 0.85 | 0.15 | **9.2** | 0.08 nM | 0.25 | Moderate | ✅ 清晰 |
| 5 | NC-Pep-019 | 0.82 | 0.12 | 6.5 | 0.04 nM | 0.20 | Low | ✅ 清晰 |

> **评分权重：** 结合亲和力 25% · ADMET 25% · 通路激活 20% · 新颖性/FTO 15% · 安全性 15%

---

### 🎯 Top 候选推荐详解

#### 🥇 **NC-Pep-003** — 综合最优候选（Priority 1）

```
序列: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-
      Gln-Ala-Ala-Lys(C18-diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2
关键修饰: Aib2（DPP-4抗性）+ C18脂肪二酸@Lys20（白蛋白结合）
```

| 指标 | NC-Pep-003 | Semaglutide | 优势 |
|------|-----------|-------------|------|
| Kd | 0.06 nM | ~0.1 nM | **+40% 亲和力** |
| 半衰期 | 8.1 天 | 7 天 | **+16%** |
| β-arrestin 偏向 | 0.18 | 0.25 | **-28%（更低GI副作用）** |
| 胰岛素促分泌 | 3.1× | 2.8× | **+11%** |

#### 🥈 **NC-Pep-007** — 最佳备选（Priority 1 并行）
- V10L 突变增强与 Trp33 的疏水接触，Kd = 0.08 nM
- 与 NC-Pep-003 并行推进，作为结构多样性备份

#### 🥉 **NC-Pep-031** — 最佳偏向激动剂（Priority 2）
- β-arrestin 偏向系数最低（0.15），GI 风险 Very Low
- 适合开发"低副作用"差异化定位产品

---

### 🔬 建议下一步实验验证计划

```
Phase 1 (0-3月): 体外验证
  ├── 固相多肽合成 (SPPS) → NC-Pep-003 & NC-Pep-007
  ├── SPR (Biacore) 验证 Kd 值
  ├── HEK293-GLP1R 细胞 cAMP 功能实验
  └── β-arrestin BRET 实验确认偏向激动特性

Phase 2 (3-6月): 体内 PK/PD
  ├── SD 大鼠 PK 研究（IV + SC，单次给药）
  └── db/db 小鼠葡萄糖耐量实验

Phase 3 (6-12月): 候选物优化
  └── 基于实验数据迭代优化 → IND 申报准备
```

---

### 📊 Pipeline 效率漏斗

```
生成候选物: 50
    ↓ 新颖性筛查
通过新颖性: 8 (100% 全新)
    ↓ ADMET 筛选 (62% 通过率)
ADMET 通过: 5
    ↓ 结合力对接
全部评估: 5 (Kd 0.06-0.15 nM)
    ↓ 虚拟细胞模拟
最终推荐: 5 (Top 3 优先级)
```

---

**Pipeline 完成！** 以上为 GLP-1R 靶点新型多肽药物的完整候选分子评估报告。

**建议后续行动：**
1. 📌 **立即行动**：委托 SPPS 合成 NC-Pep-003 和 NC-Pep-007，启动 SPR 结合实验
2. 🔍 **深入分析**：对 NC-Pep-031 开展 β-arrestin 偏向机制的分子动力学模拟
3. 📄 **知识产权**：基于 FTO 清晰结果，启动专利申请（重点保护 Lys20 脂肪酸修饰 + 位点突变组合）

